Baird raised the firm’s price target on Apellis (APLS) to $52 from $50 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results where the strong start for its kidney launch was overshadowed by the Syfovre miss.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis price target lowered to $45 from $52 at Citi
- Apellis price target lowered to $45 from $57 at H.C. Wainwright
- Apellis Pharmaceuticals Reports Strong Q3 2025 Earnings
- Apellis Pharmaceuticals: Strong Market Position and Growth Potential Amidst Challenges
- Resilient Revenue and Strategic Positioning Support Buy Rating for Apellis Pharmaceuticals